Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
Sa Rang Kim, Julia M. Lewis, Benoit M. Cyrenne, et al.
Oncotarget (2018) Vol. 9, Iss. 49, pp. 29193-29207
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Targeting apoptosis in cancer therapy
Benedito A. Carneiro, Wafik S. El‐Deiry
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 395-417
Open Access | Times Cited: 1942
Apoptosis and Pharmacological Therapies for Targeting Thereof for Cancer Therapeutics
Vishakha Singh, Amit Khurana, Umashanker Navik, et al.
Sci (2022) Vol. 4, Iss. 2, pp. 15-15
Open Access | Times Cited: 73
Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Zhiqiang Wang, Zhao-Cong Zhang, Yuyang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 69
Epigenetic polypharmacology: A new frontier for epi‐drug discovery
Daniela Tomaselli, Alessia Lucidi, Dante Rotili, et al.
Medicinal Research Reviews (2019) Vol. 40, Iss. 1, pp. 190-244
Open Access | Times Cited: 96
Targeting BET bromodomain proteins in cancer: The example of lymphomas
Filippo Spriano, Anastasios Stathis, Francesco Bertoni
Pharmacology & Therapeutics (2020) Vol. 215, pp. 107631-107631
Closed Access | Times Cited: 58
BET Proteins as Attractive Targets for Cancer Therapeutics
Joanna Sarnik, Tomasz Popławski, Paulina Tokarz
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11102-11102
Open Access | Times Cited: 53
Mechanisms of venetoclax resistance and solutions
Jiachen Liu, Yidong Chen, Lihua Yu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 32
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes
Jingjing Chen, Yalei Li, Jie Zhang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112868-112868
Closed Access | Times Cited: 49
Novel targeted therapies of T cell lymphomas
Katarzyna Iżykowska, Karolina Rassek, Dorota Korsak, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 49
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
Lucía Prieto‐Torres, Socorro María Rodríguez‐Pinilla, Arantza Onaindía, et al.
Haematologica (2019) Vol. 104, Iss. 2, pp. 226-235
Open Access | Times Cited: 47
Review of cancer cell resistance mechanisms to apoptosis and actual targeted therapies
Merve Kulbay, Adeline Paimboeuf, Derman Ozdemir, et al.
Journal of Cellular Biochemistry (2021) Vol. 123, Iss. 11, pp. 1736-1761
Closed Access | Times Cited: 33
Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma
Lei Zhao, Jean‐Phillip Okhovat, Eric Hong, et al.
Neoplasia (2018) Vol. 21, Iss. 1, pp. 82-92
Open Access | Times Cited: 42
Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
Diana Reyes-Garau, Marcelo Lima Ribeiro, Gaël Roué
Cancers (2019) Vol. 11, Iss. 10, pp. 1483-1483
Open Access | Times Cited: 38
Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer
W. Douglas Fairlie, Erinna F. Lee
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 2841-2841
Open Access | Times Cited: 30
HDAC10 and its implications in Sézary syndrome pathogenesis
Monika Pieniawska, Karolina Rassek, Bogumiła Skwara, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Sara Yumeen, Fatima N. Mirza, Julia M. Lewis, et al.
Blood Advances (2020) Vol. 4, Iss. 10, pp. 2213-2226
Open Access | Times Cited: 31
The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells
Stephanie Laszig, Cathinka Boedicker, Tim Weiser, et al.
Cancer Letters (2020) Vol. 486, pp. 46-57
Closed Access | Times Cited: 28
Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy
Benu Chaudhary, Preeti Arya, Vikas Sharma, et al.
Bioorganic Chemistry (2025), pp. 108388-108388
Closed Access
Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
Sara Yumeen, Michael Girardi
The Yale Journal of Biology and Medicine (2020) Vol. 93, Iss. 1, pp. 111-121
Closed Access | Times Cited: 26
Update on Biology of Cutaneous T-Cell Lymphoma
Zaw Phyo, Satish Shanbhag, Sima Rozati
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 26
Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma
Fani Karagianni, Christina Piperi, Berta Casar, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 1070-1070
Open Access | Times Cited: 13
Integrative data modeling from lung and lymphatic cancer predicts functional roles for miR-34a and miR-16 in cell fate regulation
Shantanu Gupta, Daner A. Silveira, Florencia María Barbé‐Tuana, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 18
Current status in the discovery of dual BET/HDAC inhibitors
Qinghua Ren, Gao Wen-qian
Bioorganic & Medicinal Chemistry Letters (2020) Vol. 31, pp. 127671-127671
Closed Access | Times Cited: 14
Enhancing venetoclax activity in hematological malignancies
Toshihisa Satta, Steven Grant
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 7, pp. 697-708
Open Access | Times Cited: 12
Targeting epigenetic mechanisms to overcome venetoclax resistance
Gabriel Prado, Charlotte L Kaestner, Jonathan D. Licht, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2021) Vol. 1868, Iss. 8, pp. 119047-119047
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top